Efficacy of drug therapies in post-nasal drip

Drug efficacy study as treatment for post-nasal drip in laryngopharyngeal reflux

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004740

Enrollment

Registered

2020-02-14

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The eligible subjects with post-nasal drip associated laryngopharyngeal reflux will be randomized into one of acetylcysteine 200mg twice daily-arm or acetylcysteine 200mg and ilaprazole 10mg tw

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients over 19 year - Patient who has post-nasal drip associated laryngopharyngeal reflux - Outpatient or inpatient of this hospital - Patients who agree to participate in this clinical trial

Exclusion criteria

Exclusion criteria: - Patients who don’t agree to participate in this clinical trial - Patients who don’t visit during this clinical trial period at least once

Design outcomes

Primary

Measure	Time frame
Questionnaires score	—

Secondary

Measure	Time frame
Endoscope score	—

Countries

Korea, Republic of

Contacts

Public ContactHanjin Jung

Chungbuk National University Hospital

Outcome results